Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04248439 · ClinicalTrials.gov registry record · Phase 2
Gene Therapy for Fanconi Anemia, Complementation Group A
A Phase 2 study of Fanconi Anemia Complementation Group A, sponsored by Rocket Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT04248439: Active Phase 2 study of Fanconi Anemia Complementation Group A, sponsored by Rocket Pharmaceuticals.
NCT04248439 is a Phase 2 study of Fanconi Anemia Complementation Group A that is active but no longer recruiting, run by Rocket Pharmaceuticals. The registered enrollment target is 5 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04248439, a Phase 2 study of Fanconi Anemia Complementation Group A, is active but no longer recruiting, sponsored by Rocket Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A). Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.
Conditions Studied
Interventions
- BIOLOGICAL RP-L102
Study Locations (2)
California
- Stanford University - Stanford
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2026-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04248439
The ClinicalTrials.gov registry entry for NCT04248439 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rocket Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fanconi Anemia Complementation Group A appearing as the primary indexed condition, and to 1 intervention - of which RP-L102 is the first listed.
NCT04248439 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04248439 about?
NCT04248439 is a clinical study titled "Gene Therapy for Fanconi Anemia, Complementation Group A". The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A). Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiv...
What is the current status of trial NCT04248439?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-07-15. Estimated completion is 2026-05-05.
What conditions does trial NCT04248439 study?
This clinical trial studies the following conditions: Fanconi Anemia Complementation Group A.
What interventions are being tested in trial NCT04248439?
The interventions under investigation include: RP-L102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04248439?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04248439 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.